WO2003070229A3 - Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes - Google Patents

Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes Download PDF

Info

Publication number
WO2003070229A3
WO2003070229A3 PCT/EP2003/001807 EP0301807W WO03070229A3 WO 2003070229 A3 WO2003070229 A3 WO 2003070229A3 EP 0301807 W EP0301807 W EP 0301807W WO 03070229 A3 WO03070229 A3 WO 03070229A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
autoimmune diseases
proteinase inhibitors
activation
diseases
Prior art date
Application number
PCT/EP2003/001807
Other languages
German (de)
English (en)
Other versions
WO2003070229A2 (fr
Inventor
Uwe Jacob
Peter Sondermann
Robert Huber
Original Assignee
Max Planck Gesellschaft
Uwe Jacob
Peter Sondermann
Robert Huber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10241411A external-priority patent/DE10241411A1/de
Application filed by Max Planck Gesellschaft, Uwe Jacob, Peter Sondermann, Robert Huber filed Critical Max Planck Gesellschaft
Priority to AU2003206945A priority Critical patent/AU2003206945A1/en
Publication of WO2003070229A2 publication Critical patent/WO2003070229A2/fr
Publication of WO2003070229A3 publication Critical patent/WO2003070229A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'au moins une substance inhibant des protéases et, en particulier, des sérine-protéases, pour le traitement de maladies ou d'états qui sont caractérisés par des réactions immunitaires exubérantes, en particulier par activation excessive ou indésirable de cellules immunitaires, production d'anticorps ou activation de compléments.
PCT/EP2003/001807 2002-02-22 2003-02-21 Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes WO2003070229A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003206945A AU2003206945A1 (en) 2002-02-22 2003-02-21 Use of proteinase inhibitors in the treatment of autoimmune diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10207744 2002-02-22
DE10207744.4 2002-02-22
DE10241411.4 2002-09-06
DE10241411A DE10241411A1 (de) 2002-02-22 2002-09-06 Verwendung von Proteinaseinhibitoren zur Behandlung von Autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
WO2003070229A2 WO2003070229A2 (fr) 2003-08-28
WO2003070229A3 true WO2003070229A3 (fr) 2004-03-04

Family

ID=27758411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001807 WO2003070229A2 (fr) 2002-02-22 2003-02-21 Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes

Country Status (2)

Country Link
AU (1) AU2003206945A1 (fr)
WO (1) WO2003070229A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4898091B2 (ja) 2002-03-11 2012-03-14 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー ウロキナーゼの阻害剤、それらの製造および使用
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
MX2008002702A (es) * 2005-08-29 2008-03-18 Wilex Ag Compuestos de oxadiazol como inhibidores de uroquinasa.
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP2355826A1 (fr) * 2008-11-07 2011-08-17 The Cleveland Clinic Foundation Composés et procédés favorisant la différenciation des précurseurs d'oligodendrocytes
EP2590945B1 (fr) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Inhibiteurs de la sérine protéase
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
WO2016144654A1 (fr) 2015-03-09 2016-09-15 Washington University Inhibiteurs d'enzymes d'activation de facteur de croissance
CN110785172A (zh) * 2017-07-21 2020-02-11 红山生物医药有限公司 Wx-uk1及其产品wx-671用于治疗非癌性医学病症的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013061A1 (fr) * 1996-09-24 1998-04-02 Cv Therapeutics, Inc. Inhibition de proteasome 26s et 20s au moyen d'indanones
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
US5932567A (en) * 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
WO2000061608A2 (fr) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Inhibiteurs de faible poids moleculaire des proteases du complement
US6358928B1 (en) * 1999-11-22 2002-03-19 Enzyme Systems Products Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases
WO2002053516A2 (fr) * 2001-01-08 2002-07-11 Laboratoires Fournier Sa Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
WO2003037892A1 (fr) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
US5932567A (en) * 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
WO1998013061A1 (fr) * 1996-09-24 1998-04-02 Cv Therapeutics, Inc. Inhibition de proteasome 26s et 20s au moyen d'indanones
WO2000061608A2 (fr) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Inhibiteurs de faible poids moleculaire des proteases du complement
US6358928B1 (en) * 1999-11-22 2002-03-19 Enzyme Systems Products Peptidyl sulfonyl imidazolides as selective inhibitors of serine proteases
WO2002053516A2 (fr) * 2001-01-08 2002-07-11 Laboratoires Fournier Sa Derives de la n(phenylsulfonyl)glycine et leur utilisation en therapeutique
WO2003037892A1 (fr) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUNGL AJ ET AL: "Time-Resolved Fluorescence Anisotropy of HIV-1 Protease Inhibitor Complexes Correlates with Inhibitory Activity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA, US, vol. 37, 13 February 1998 (1998-02-13), pages 2778 - 2786, XP002191310, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
WO2003070229A2 (fr) 2003-08-28
AU2003206945A8 (en) 2003-09-09
AU2003206945A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2002000860A3 (fr) Nouvelles proteases
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
WO2003097794A3 (fr) Amorces oligonucleotidiques universelles marquees et procedes d'utilisation
SE0201980D0 (sv) Novel compounds
WO2003009855A3 (fr) Composes organophosphores pour l'activation de cellules t gamma/delta
IL172506A0 (en) New biological entities and the use thereof
WO2001083782A3 (fr) Nouvelles proteases
AU2003243097A1 (en) Novel compounds
AU8738401A (en) Novel kallikrein gene
WO2003070229A3 (fr) Utilisation d'inhibiteurs de proteinases pour le traitement de maladies auto-immunes
TR199902751T2 (xx) Proteaz inhibit�rleri.
WO2004087735A3 (fr) Anticorps proteolytiques et covalents
GB0216001D0 (en) Process and composition
WO2004043379A3 (fr) Composes chimiques
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2003076391A3 (fr) Inhibiteurs de l'urokinase, leur production et leur utilisation
WO2004065406A3 (fr) Peptides derives de rantes
AU2003303076A1 (en) Cathepsin cysteine protease inhibitors and their use
WO2002094881A3 (fr) Anticorps monoclonal neutralisant l'activite de la cathepsine b et utilisations associees
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
EP1529837A3 (fr) Micro-organisme produisants des dipeptides et procédé de production de dipeptides par ces micro-organismes
AU2003255287A1 (en) Use of a proteasome inhibitor in the treatment of fibrotic diseases
AU2002362447A1 (en) Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
NO20053575L (no) Metallprotease proteiner

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP